Linked Life Data

12503271

Source:http://linkedlifedata.com/resource/pubmed/id/12503271

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2002-12-30
pubmed:abstractText
There is a disclosure of the results of the therapy of gastroesophageal reflux disease at the stage of reflux esophagitis with gastrosidin (famotidine), 40 mg twice a day during 4-8 weeks. The dosage of gastrosidin (famotidine) was reduced to 40 mg a day only if side effects appeared: diarrhea (4) and urticaria (3). After four weeks of treatment, endoscopic symptoms of esophagitis disappeared in 17 patients out of 28 (60.7%), and a positive dynamics was recorded in 11 patients. After eight weeks of treatment, the disappearance of endoscopic symptoms of esophagitis was recorded in 7 patients out of 8 (including the healing of the peptic esophagus ulcer in one patient). Three patients (who were feeling good) refused to undergo a control endoscopic examination.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1682-8658
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
30-3, 131
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
[Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
pubmed:affiliation
Central Scientific Research Institute of Gastroenterology, Moscow.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract